The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
Luca FilippiAgostino ChiaravallotiOrazio SchillaciOreste BagniPublished in: Expert review of anticancer therapy (2020)
PSMA-based TAT holds the promise of becoming a powerful tool for the management of mCRPC. Nevertheless, several issues have still to be addressed, especially concerning TAT toxicity. Furthermore, several efforts have to be made for identifying the more adequate alpha-emitter (225Ac vs 213Bi) with a view to the patient's tailored therapeutic approach.